


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-50 (canceled)

51. (currently amended) A compound of the formula I(A-F) having the following structure:



IA-IF

wherein: the carbon atom designated \* is in the R or S configuration;

R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>;

R<sup>2</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R<sup>3</sup> is H, -OR<sup>11</sup>, -S(O)<sub>n</sub>R<sup>12</sup>, -S(O)<sub>n</sub>NR<sup>11</sup>R<sup>12</sup>, -C(O)R<sup>12</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, -O(phenyl), -OC(O)R<sup>13</sup>, or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy, or wherein when R<sup>3</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl,

C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>; provided that for compounds of formula IA, R<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>;

provided that for compounds of formula IB, R<sup>3</sup> is -O(phenyl), -O(benzyl), -OC(O)R<sup>13</sup> or S(O)<sub>n</sub>R<sup>12</sup>, each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy;

R<sup>4</sup> is H, halogen, -S(O)<sub>n</sub>R<sup>12</sup>, -S(O)NR<sup>11</sup>R<sup>12</sup>, -CN, -C(O)R<sup>12</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, -NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, -O(phenyl), -OC(O)R<sup>13</sup>, or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy and wherein when R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>; provided that for compounds of formula IC, R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, each of which is optionally substituted; provided that for compounds of formula ID, R<sup>4</sup> is -O(phenyl), -O(benzyl), -OC(O)R<sup>13</sup>, -NR<sup>11</sup>R<sup>12</sup> or -S(O)<sub>n</sub>R<sup>12</sup>, each of -O(phenyl) and -O(benzyl) being optionally substituted, wherein R<sup>3</sup> and R<sup>4</sup> are not both H;

R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> in compounds of each of the formulae IA, IB, IC, ID, IE and IF are each independently H, halogen, -OR<sup>11</sup>, -S(O)<sub>n</sub>R<sup>12</sup>, -CN, -C(O)R<sup>12</sup>, -NR<sup>11</sup>R<sup>12</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, -NR<sup>11</sup>C(O)R<sup>12</sup>, -NR<sup>11</sup>C(O)<sub>2</sub>R<sup>12</sup>, -NR<sup>11</sup>C(O)NR<sup>12</sup>R<sup>13</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, wherein when each of R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>, or R<sup>5</sup> and R<sup>6</sup> or R<sup>6</sup> and R<sup>7</sup> may together be -O-C(R<sup>12</sup>)<sub>2</sub>-O-; provided that for compounds of formula IE at least one of R<sup>5</sup> or R<sup>7</sup> is fluoro, chloro, or methyl; or R<sup>5</sup> and R<sup>6</sup> are together

$-O-C(R^{12})_2-O-$  in compounds of the formulae IE, but only where  $R^7$  is fluoro, chloro or methyl; or  $R^7$  and  $R^6$  are together  $-O-C(R^{12})_2-O-$  in compounds of the formulae IE, but only where  $R^5$  is fluoro, chloro or methyl;

$R^8$  is H or halogen, provided that for compounds of formula IF,  $R^8$  is halogen;

$R^9$  and  $R^{10}$  are each independently H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl,  $-C(O)R^{13}$ , phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy; or  $R^9$  and  $R^{10}$  are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

$R^{11}$  is H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl,  $-C(O)R^{13}$ , phenyl or benzyl, where  $R^{11}$  is a  $C_1$ - $C_4$  alkyl, phenyl or benzyl group, then said group is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy;

$R^{12}$  is H, amino,  $C_1$ - $C_4$  alkyl, ( $C_1$ - $C_4$  alkyl)amino,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl, phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl and  $C_1$ - $C_4$  alkoxy; or  $R^{11}$  and  $R^{12}$  are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

provided that only one of  $R^9$  and  $R^{10}$  are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

$R^{13}$  is  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl or phenyl;

$n$  is 0, 1, or 2, and;

aryl is phenyl which is optionally substituted 1-3 times with halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl and  $C_1$ - $C_4$  alkoxy, or

an oxide thereof, or a pharmaceutically acceptable salt thereof and, wherein if  $R^3$  is  $-S(O)_nR^{12}$ ,  $n$  cannot be 0, and wherein if  $R^3$  is  $-\underline{OR^{11}}, R^{11}-\underline{OR^9}, R^9$  cannot be hydrogen.

52. (previously presented) The compound of claim 51, wherein  $R^1$  is  $C_1$ - $C_3$  alkyl.

53. (previously presented) The compound of claim 52, wherein  $R^1$  is  $CH_3$ .
54. (previously presented) The compound of claim 51, wherein  $R^2$  is H,  $C_1$ - $C_4$  alkyl or  $C_1$ - $C_6$  haloalkyl.
55. (previously presented) The compound of claim 54, wherein  $R^2$  is H or  $CH_3$ .
56. (previously presented) The compound of claim 51, wherein  $R^3$  is H or  $R^3$  is  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl,  $-CN$ ,  $-OR^9$  and  $-NR^9R^{10}$  or  $R^3$  is  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$  optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy.
57. (previously presented) The compound of claim 56, wherein  $R^3$  is methyl, ethyl, propyl, or isopropyl.
58. (previously presented) The compound of claim 56, wherein  $R^3$  is  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$ , each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy.
59. (previously presented) The compound of claim 56, wherein  $R^3$  is H.
60. (previously presented) The compound of claim 51, wherein  $R^4$  is H, or  $R^4$  is  $-NR^{11}R^{12}$  or  $R^4$  is  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted, or wherein  $R^4$  is  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy.
61. (previously presented) The compound of claim 60, wherein  $R^4$  is methyl, ethyl, propyl, or isopropyl.

62. (previously presented) The compound of claim 60, wherein  $R^4$  is -O(phenyl) or -O(CH<sub>2</sub>)(phenyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy.

63. (previously presented) The compound of claim 60, wherein  $R^4$  is H.

64. (previously presented) The compound of claim 51, wherein  $R^4$  is halogen.

65. (previously presented) The compound of claim 51, wherein one of  $R^3$  and  $R^4$  is H and the other is CH<sub>3</sub>.

66. (previously presented) The compound of claim 51, wherein  $R^5$ ,  $R^6$  and  $R^7$  are each H, halogen, -OR<sup>11</sup>, -NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl and substituted C<sub>1</sub>-C<sub>6</sub> alkyl.

67. (previously presented) The compound of claim 66, wherein  $R^5$ ,  $R^6$  and  $R^7$  are each H.

68. (previously presented) The compound of claim 66, wherein one of  $R^5$  or  $R^7$  is F, Cl, or Me and the other of  $R^5$  or  $R^7$  and  $R^6$  are H, halogen, -OR<sup>11</sup>, -NR<sup>11</sup>R<sup>12</sup>, or optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl.

69. (previously presented) The compound of claim 68, wherein  $R^5$  is F, Cl or Me; and  $R^7$  is H.

70. (previously presented) The compound of claim 68, wherein  $R^5$  is F, Cl or Me; and  $R^6$  is H.

71. (previously presented) The compound of claim 51, wherein  $R^8$  is halogen.

72. (previously presented) The compound of claim 71, wherein  $R^8$  is fluoro.

73. (currently amended) The compound of claim 51, wherein:

$R^1$  is  $C_1$ - $C_3$  alkyl;

$R^2$  is H,  $C_1$ - $C_4$  alkyl or  $C_1$ - $C_6$  haloalkyl;

$R^3$  is  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted, or  $R^3$  is  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , each of which is optionally substituted, or  $R^3$  is H;

$R^4$  is H,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which, other than H, is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl,  $-CN$ ,  $-OR^9$  and  $-NR^9R^{10}$ , or  $R^4$  is  $-NR^{11}R^{12}$ ,  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , wherein said  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy[.];

or  $R^4$  is halogen;

$R^5$ ,  $R^6$  and  $R^7$  are each halogen,  $-OR^{11}$ ,  $-NR^{11}R^{12}$ , or  $C_1$ - $C_6$  alkyl, or one of  $R^5$  and  $R^7$  is Cl, F or Me and the other of  $R^5$  and  $R^7$  and  $R^6$  is H, halogen,  $-NR^{11}R^{12}$ ,  $C_1$ - $C_6$  alkyl or substituted  $C_1$ - $C_6$  alkyl.

74. (previously presented) The compound of claim 51, wherein:

$R^1$  is  $CH_3$ ;

$R^2$  is H or  $CH_3$ ;

$R^3$  is H, methyl, ethyl, propyl, isopropyl,  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$ , wherein said  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$  is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy;

$R^4$  is H, F, methyl, ethyl, propyl, isopropyl,  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$ , wherein said  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$  is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy;

$R^5$ ,  $R^6$  and  $R^7$  are each H or  $R^5$  is F, Cl or Me, or one of  $R^6$  or  $R^7$  is H and the other of  $R^6$  and  $R^7$  is halogen,  $-OR^{11}$ ,  $-NR^{11}R^{12}$ , or optionally substituted  $C_1$ - $C_6$  alkyl.

75. (previously presented) The compound of claim 73, wherein  $R^8$  is halogen.

76. (previously presented) The compound according to claim 51, wherein the carbon atom designated \* is in the R configuration.

77. (previously presented) The compound according to claim 51, wherein the carbon atom designated \* is in the S configuration.

78. (previously presented) A composition comprising a mixture of stereoisomeric compounds of claim 51 wherein the carbon atom designated \* is in the S or R configuration.

79. (previously presented) The compound according to claim 51, selected from the group consisting of the following compounds:

4-(4-methoxy)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro-4-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-4-(3-fluoro-4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(4-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(4-chloro-3-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-dichloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
7-ethyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-difluoro)phenyl-7-ethyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
7-fluoro-4-(3-fluoro-4-methoxy)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
7-fluoro-4-(3-fluoro-4-methyl)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
7-fluoro-4-(4-chloro-3-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-difluoro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
2-methyl-4-phenyl-7-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline;  
4-phenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-7-fluoro-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-7-phenoxy-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
7-(4-methoxy)phenoxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
7-benzyloxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,5-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro-4-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-dichloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(4-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(4-chloro-3-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(4-methoxy)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(4-cyano)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(4-trifluoromethyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
2-methyl-8-(N-methylamino)methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
8-(hydroxy)methyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
2-methyl-4-phenyl-8-sulfonamide-1,2,3,4-tetrahydroisoquinoline;  
2-methyl-8-(N-methyl)sulfonamide-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,5-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro-5-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,5-difluoro)phenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;  
2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinoliny)-N-methylmethanamine;  
N-methyl(2-methyl-4-phenyl-1,2,3,4-tetrahydro-  
7-isoquinoliny)-N-methylmethanamine;  
(2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinoliny)methanol; and  
an oxide thereof, or a pharmaceutically acceptable salt thereof.


80. (previously presented) The compound according to claim 51, selected from the group consisting of the following compounds:



R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
Me	H	H	Me	H	OMe	H	H
Me	H	H	Me	H	F	H	H
Me	H	H	Me	F	H	H	H
Me	H	H	Me	F	F	H	H
Me	H	H	Me	Me	F	H	H
Me	H	H	Me	Cl	F	H	H
Me	H	H	Me	Cl	H	H	H
Me	H	H	Me	H	Me	H	H
Me	H	H	Me	F	Me	H	H
Me	H	H	Me	H	Cl	H	H
Me	H	H	Me	F	Cl	H	H
Me	H	H	Me	Cl	Cl	H	H
Me	H	H	Et	H	H	H	H
Me	H	H	Et	F	F	H	H
Me	H	H	F	F	OMe	H	H
Me	H	H	F	F	Me	H	H
Me	H	H	F	F	Cl	H	H
Me	H	H	F	F	F	H	H
Me	H	H	F	Cl	H	H	H
Me	H	H	CF <sub>3</sub>	H	H	H	H
Me	Me	H	Me	H	H	H	H
Me	H	Me	Me	H	H	H	H
Me	H	Me	F	H	H	H	H
Me	H	H	O(Ph)	H	H	H	H
Me	H	H	O(4-OMePh)	H	H	H	H
Me	H	H	O(CH <sub>2</sub> Ph)	H	H	H	H
Me	H	Me	H	H	F	H	H
Me	H	Me	H	F	F	H	H
Me	H	Me	H	F	H	F	H
Me	H	Me	H	F	H	H	H
Me	H	Me	H	Me	F	H	H
Me	H	Me	H	Cl	F	H	H

R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
Me	H	Me	H	Cl	Cl	H	H
Me	H	Me	H	Cl	H	H	H
Me	H	Me	H	H	Cl	H	H
Me	H	Me	H	F	Cl	H	H
Me	H	Me	H	H	OMe	H	H
Me	H	Me	H	H	CN	H	H
Me	H	Me	H	H	CF <sub>3</sub>	H	H
Me	H	Me	H	H	Me	H	H
Me	H	CH <sub>2</sub> NHMe	H	H	H	H	H
Me	H	CH <sub>2</sub> OH	H	H	H	H	H
Me	H	SO <sub>2</sub> NH <sub>2</sub>	H	H	H	H	H
Me	H	SO <sub>2</sub> NHMe	H	H	H	H	H
Me	H	H	Me	F	H	F	H
Me	H	H	Me	F	H	Cl	H
Me	Me	H	Me	F	H	F	H
Me	H	H	Me	F	F	F	H
Et	H	H	Me	H	F	H	H
Me	H	H	CH <sub>2</sub> NH <sub>2</sub>	H	H	H	H
Me	H	H	CH <sub>2</sub> NHMe	H	H	H	H
Me	H	H	CH <sub>2</sub> OH	H	H	H	H

81. (previously presented) The compound according to claim 51, wherein, the compound has the formula:



, where:

R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>
Me	H	F	F
Me	F	H	F
Me	H	F	H
Me	H	H	F.

82. (previously presented) The compound according to claim 79, which is the (+) stereoisomer.

83. (previously presented) The compound according to claim 79, which is the (-) stereoisomer.

84. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 51.

85. (previously presented) A method of treating a disorder selected from the group consisting of attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, panic attacks, Parkinsonism and phobia, obesity, late luteal phase syndrome or narcolepsy, cocaine addiction, amphetamine addiction, rejection sensitivity, and lack of mental or physical energy, wherein said method comprises:

administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 51, or a pharmaceutically acceptable salt thereof.

86-89. (canceled)

90. (previously presented) The method of claim 85 wherein the (+)-stereoisomer of the compound is employed.

91. (previously presented) The method of claim 85, wherein the (-)-stereoisomer of the compound is employed.

92. (previously presented) The method of claim 85, wherein the disorder is attention deficit disorder or hyperactivity disorder.

93. (canceled)